{'fraction_non_alphanumeric': 0.038747852643634284, 'fraction_numerical': 0.02901317045237641, 'mean_word_length': 5.114352392065344, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diabetes and Risk of COVID-19 Mortality

To the Editor A growing body of evidence has suggested that patients with diabetes who developed the novel corona virus disease (COVID-19) might have shown increased mortality. Biologically, patients with diabetes have glycemic instability, impaired immune response, and associated comorbidities such as obesity and heart diseases, factors that could explain the high COVID-19 mortalities among patients with diabetes. Epidemiologically, numerous studies assessed the possible relationship between diabetes and COVID-19mortalities, but most of themwere limited by the small sample size in addition to reaching inconsistent findings. We, therefore, combined the results of the published studies via a meta-analysis to precisely detect the excess risk of COVID-19 mortality attributed to diabetes. First, we searched MEDLINE (PubMed), Web of Science, and Scopus for potential studies published before May 31, 2020, using relevant search terms (diabetes OR diabetes mellitus OR type 2 diabetes OR DM) AND (COVID-19 OR SARS-COV 2 OR coronavirus) AND (outcomes OR mortality OR fatality OR deaths). The study was considered eligible if 1) it was published in English, 2) the exposure was COVID-19 patients with diabetes in comparison with COVID-19 patients without diabetes, 3) the outcome was COVID-19 mortality, and 4) the number of COVID-19 patients with diabetes is 50 or more. After reviewing the abstracts of all studies detected by the primary search, we reached a shortlist of studies from which the


Diabetes and Risk of COVID-19 Mortality
A Systematic Review and Meta-Analysis To the Editor A growing body of evidence has suggested that patients with diabetes who developed the novel corona virus disease (COVID-19) might have shown increased mortality. Biologically, patients with diabetes have glycemic instability, impaired immune response, and associated comorbidities such as obesity and heart diseases, factors that could explain the high COVID-19 mortalities among patients with diabetes. 1 Epidemiologically, numerous studies assessed the possible relationship between diabetes and COVID-19 mortalities, but most of them were limited by the small sample size in addition to reaching inconsistent findings. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] We, therefore, combined the results of the published studies via a meta-analysis to precisely detect the excess risk of COVID-19 mortality attributed to diabetes.
First, we searched MEDLINE (PubMed), Web of Science, and Scopus for potential studies published before May 31, 2020, using relevant search terms (diabetes OR diabetes mellitus OR type 2 diabetes OR DM) AND (COVID-19 OR SARS-COV 2 OR coronavirus) AND (outcomes OR mortality OR fatality OR deaths). The study was considered eligible if 1) it was published in English, 2) the exposure was COVID-19 patients with diabetes in comparison with COVID-19 patients without diabetes, 3) the outcome was COVID-19 mortality, and 4) the number of COVID-19 patients with diabetes is 50 or more.
After reviewing the abstracts of all studies detected by the primary search, we reached a shortlist of studies from which the following relevant information was extracted: last name of the first author, country, sample size, method of diabetes diagnosis, odds ratios (ORs) with corresponding 95% confidence intervals (CIs), and the quality of studies as determined using the modified Newcastle-Ottawa Scale (NOS) ( Table 1). The fixed-or random-effects model was used to compute the pooled ORs. The I 2 was calculated to test the statistical heterogeneity across studies. A forest plot showing the ORs with their 95% CIs and study weights of the selected studies in addition to the pooled OR (95% CI) and I 2 was presented (Fig. 1). Sensitivity analysis was conducted to assess the influence of individual studies on the pooled OR and I 2 by leaving out one study and combining the remaining studies in separate analyses. Publication bias was assessed using the regression test for funnel plot asymmetry. R-3.2.0 statistical package (Metafor: A Meta-Analysis Package for R) was used for analysis.
Eventually, we retrieved a total of 831 studies before excluding 431 duplicates; 327 articles for being written in a non-English language, case reports, comments, reviews, or unrelated; 41 articles for not examining COVID-19 mortality or not including a comparison group; and 21 articles for including less than 50 COVID-19 patients with diabetes, leaving a shortlist of 15 studies for this meta-analysis. Most of the included studies were conducted in China, whereas only 5 studies were conducted out of China (3 studies in the United States and 1 study in each of Iran and Mexico). The studies included 75,200 COVID-19 patients, of which 13,609 had concomitant diabetes. According to the modified NOS, most studies were of average to good quality (Table 1).
A total of 8 studies showed statistically significant associations between diabetes and COVID-19 mortality, whereas 7 studies indicated no significant association. Combining the ORs of all studies revealed that COVID-19 patients with diabetes had an 87% higher risk of death than COVID-19 patients without diabetes (pooled OR,